|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
27,540,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.338 - $1.338 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PLx Pharma is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients are absorbed in the gastrointestinal tract via its clinically-validated and patent-protected PLxGuard™ technology. Co. has two Food and Drug Administration approved products, VAZALORE® 81 mg and VAZALORE® 325 mg, which are liquid-filled aspirin capsules for over-the-counter distribution. The complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach lining. VAZALORE delivers absorption for pain relief plus the lifesaving benefits of aspirin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Giordano Natasha |
President and CEO |
• • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,086 |
1,086 |
|
- |
|
| Jorden David Emerson |
Acting Chief Financial Officer |
• – – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
119,186 |
119,186 |
|
- |
|
| Balkema Gary S. |
Director |
– • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,445 |
5,445 |
|
- |
|
| Calhoun Kirk K |
Director |
– • – |
2017-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,675 |
1,675 |
|
- |
|
| Kagan Barry |
Director |
– • – |
2014-07-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,810 |
|
- |
|
| Dean Jack H |
Director |
– • – |
2014-05-21 |
4 |
B |
$9.00 |
$27,000 |
D/D |
3,000 |
48,917 |
2.39 |
- |
|
31 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
